E
enGene Therapeutics Inc. (ENGN)
NCM – Real Time Price. Currency in USD
1.75
-0.02 (-1.13%)
At close: Jun 26, 2026, 4:00 PM EDT
1.72
-0.03 (-1.71%)
After-hours: Jun 26, 2026, 6:42 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.75
-0.02 (-1.13%)
At close: Jun 26, 2026, 4:00 PM EDT
1.72
-0.03 (-1.71%)
After-hours: Jun 26, 2026, 6:42 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
Total debt $33.4M significantly exceeds cash reserves ($29.8M), raising financial stability concerns
Total current assets $270.0M exceed Total current liabilities $21.5M, highlighting excellent liquidity
Debt-to-equity ratio (0.1) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-42.9x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$30.6M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 12.57 | 6.05 | 10 | |
| Quick ratio | 12.57 | 5.63 | 10 | |
| Debt to Equity | 0.13 | 0.30 | 9.0 | |
| Debt to Assets | 0.11 | 1.04 | 9.0 | |
| Interest coverage | -42.91 | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | -175K | -323K | -509K | -670K |
| Operating Income | -2M | -26M | -62M | -123M | -133M |
| Net Income | 31K | -100M | -55M | -117M | -127M |
| EBITDA | -2M | -26M | -62M | -123M | -132M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 23.13 | 5.5 |
| Next quarter | N/A | 40.75 | 5.5 |
| Current year | N/A | 22.97 | 5.5 |
| Next year | N/A | 15.54 | 5.0 |
| Weighted average score | 5.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -1.59 | 2.27 | -5.29 | 3.8 |
| Y/Y | 999 | -17.08 | 15.69 | -33.06 | 5.3 |
| 3y average | 999 | -108451.67 | 21.08 | -1139.89 | 5.5 |
| 5y average | N/A | N/A | N/A | N/A | 1.0 |
| Weighted average score | 3.9 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |